Dendritic cell vaccines for cancer therapy

2001 ◽  
Vol 27 (4) ◽  
pp. 247-255 ◽  
Author(s):  
G.M. Sprinzl ◽  
L. Kacani ◽  
A. Schrott-Fischer ◽  
N. Romani ◽  
W.F. Thumfart
Keyword(s):  
Dendritic Cell ◽  
Cancer Therapy ◽  
Dendritic Cell Vaccines

scholarly journals Towards superior dendritic-cell vaccines for cancer therapy

2018 ◽  
Vol 2 (6) ◽  
pp. 341-346 ◽  
Author(s):  
Mansi Saxena ◽  
Sreekumar Balan ◽  
Vladimir Roudko ◽  
Nina Bhardwaj
Keyword(s):  
Dendritic Cell ◽  
Cancer Therapy ◽  
Dendritic Cell Vaccines

Cryopreservation of activated DC1 makes large scale dendritic cell vaccines feasible in cancer therapy

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S22-S23 ◽  
Author(s):  
Elizabeth Fitzpatrick ◽  
Shuwen Xu ◽  
Jashodeep Datta ◽  
Jessica Cintolo ◽  
Brian Czerniecki
Keyword(s):  
Dendritic Cell ◽  
Cancer Therapy ◽  
Large Scale ◽  
Dendritic Cell Vaccines

scholarly journals EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii306-iii306
Author(s):  
Daniel Landi ◽  
Gary Archer ◽  
Timothy Driscoll ◽  
Eric Lipp ◽  
Bridget Archambault ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Phase I ◽  
Malignant Glioma ◽  
Phase I Trial ◽  
Active Immunization ◽  
Monocyte Differentiation ◽  
Dendritic Cell Vaccines ◽  
Dc Vaccines ◽  
Subsequent Phase ◽  
Children And Young Adults

Abstract BACKGROUND Recurrent medulloblastoma and malignant glioma are lethal tumors that are virtually incurable. The cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed on medulloblastoma and malignant glioma but not on healthy brain. We evaluated autologous CMV pp65 RNA-pulsed dendritic cell (DC) vaccines in children and young adults in a phase I trial. METHODS Circulating monocytes were harvested using leukapheresis, differentiated into DCs, matured, and pulsed with pp65 RNA using electroporation. DCs were packaged into vaccines (2x107DC/vaccine) and administered intradermally following tetanus-diphtheria toxoid site preconditioning every 2 weeks x3, then monthly. The primary objectives of the study were to establish the feasibility of generating at least 3 vaccines and safety. An exploratory objective was to evaluate the ability of vaccination to create and enhance patient pp65-specific T cell responses. RESULTS Eleven patients were enrolled with medulloblastoma (n=3) or glioblastoma (n=8). Ages ranged from 9–30 years old (mean 15.5y). Ten of 11 patients (91%) generated at least 3 vaccines (mean 6.2). Eight patients received at least 3 vaccines. To date, 4 patients have received all generated vaccines without progression, 4 patients have progressed, and 2 patients are still receiving vaccines. There have not been any severe adverse events probably or definitely related to vaccines. More mature data will be presented at ISPNO. CONCLUSIONS Leukapheresis and monocyte differentiation is a feasible strategy for generating adequate DCs for active immunization in children with malignant brain tumors. CMV pp65 RNA-pulsed DCs are well-tolerated and immunogenic. Efficacy endpoints will be evaluated in a subsequent phase II trial.

scholarly journals Peptide and Dendritic Cell Vaccines

2006 ◽  
Vol 12 (7) ◽  
pp. 2342s-2345s ◽  
Author(s):  
Craig L. Slingluff ◽  
Victor H. Engelhard ◽  
Soldano Ferrone
Keyword(s):  
Dendritic Cell ◽  
Dendritic Cell Vaccines

The Role of NY-ESO-1 Activated Dendritic Cell Vaccines in Treating Advanced Non-small Cell Lung Cancer

CHEST Journal ◽  
2016 ◽  
Vol 149 (4) ◽  
pp. A313
Author(s):  
Yu Dan ◽  
Jianli Tang ◽  
Qiasheng Li ◽  
Huanhuan Zhang ◽  
Chengzhi Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cell ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dendritic Cell Vaccines

scholarly journals Dendritic cell vaccination for cancer therapy

Oncogene ◽  
2000 ◽  
Vol 19 (56) ◽  
pp. 6673-6679 ◽  
Author(s):  
Frank O Nestle
Keyword(s):  
Dendritic Cell ◽  
Cancer Therapy ◽  
Dendritic Cell Vaccination
Sign in / Sign up

Export Citation Format

Share Document